Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27043844 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3SMN1; SMN2HSD17B10 | |
| SCHEMBL30576874 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3SMN1; SMN2HSD17B10 | |
| SCHEMBL3235859 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3SMN1; SMN2HSD17B10 | |
| SCHEMBL1711553 | 0.85 | CHRNB2 (0.46) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16882811 | 0.85 | CHRNB2 (0.46) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL928271 | 0.85 | CHRNB2 (0.46) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1711225 | 0.85 | CHRNB2 (0.46) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL18049747 | 0.79 | HSD11B1 (0.39) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL18049609 | 0.79 | USP2 (0.36) | CHRM2CHRM1CHRM3SMN1; SMN2CHRNB2 | |
| SCHEMBL24502378 | 0.79 | CHRM2 (0.56) | CHRM2CHRM1CHRM3SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | CHRM2 519/4885CHRM1 359/4885CHRM3 547/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | CHRM2 519/4885CHRM1 359/4885CHRM3 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.